The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksJtc Plc Regulatory News (JTC)

Share Price Information for Jtc Plc (JTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 842.00
Bid: 844.00
Ask: 846.00
Change: 4.00 (0.48%)
Spread: 2.00 (0.237%)
Open: 845.00
High: 847.00
Low: 839.00
Prev. Close: 838.00
JTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Trading Update and Notice of Results

25 Jul 2023 07:00

RNS Number : 0001H
JTC PLC
25 July 2023
 

PRE-CLOSE INTERIM UPDATE AND NOTICE OF RESULTS

 

 

25 July 2023

 

JTC PLC

(the "Company" and together with its subsidiaries "JTC" or the "Group")

 

Pre-close Interim Trading Update and Notice of Results

 

JTC's growth continues to accelerate

 

JTC, the global professional services business, today issues the following trading update in advance of its interim results for the period ended 30 June 2023.

 

The Group continues to trade very strongly. Net organic growth has accelerated from the 12% delivered at full year 2022 and is significantly above the Company's medium-term guidance range of 8% to 10%, with both Divisions performing very well. We have seen record H1 new business wins of £14.6 million, up 15.9% on the same period last year (H1 2022: £12.6 million). Underlying EBITDA margin is at the lower end of the established medium term guidance range of 33% - 38%, as the Group continues to invest in the business to drive further growth. The Board expects the Company to deliver full year 2023 results at least in line with market expectations.[1]

 

The Group also continues to deliver on its inorganic growth strategy, sourcing high-quality opportunities that fit the Group's acquisition criteria whilst remaining disciplined on price. The Company announced the acquisition of South Dakota Trust Company ("SDTC"), making JTC the leading independent provider of administration services to the US personal trust sector, for a maximum consideration of $270 million on 14 June 2023. This is expected to complete before the end of August 2023 as previously announced. The integration of New York Private Trust Company ("NYPTC"), which completed on 1 November 2022, is progressing well and the business is trading in line with expectations. The Group continues to maintain an active M&A pipeline across both Divisions that is aligned to the Company's strategic priorities, including further opportunities in the high growth US market.

 

Cash conversion was strong, in line with levels typically seen in the first half of the year, and the Company expects to achieve its guidance range of 85% to 90% for the full year. Leverage at the end of June was below the guidance range of 1.5 to 2.0 times underlying EBITDA as a result of the timing of the SDTC equity fund raise during the period. Following completion of the SDTC deal, leverage is still expected to be below 2.0 times reported underlying EBITDA by the year-end, as previously announced.

 

The Group will deliver on its Galaxy era business plan to double in size from 2020 by the end of this year, two years' earlier than planned. JTC continues to see significant growth potential in its markets in the short, medium and long term, and will share details of its next multi-year business plan era, Cosmos, at the time of its interim results on 12 September 2023.

 

 

Nigel Le Quesne, CEO of JTC PLC, said:

 

"I am delighted to report that JTC's growth momentum continues to accelerate. Net organic growth is excellent, well ahead of our medium-term guidance, and, as highlighted by our acquisition of SDTC, we continue to realise the significant inorganic growth potential that exists in our global marketplace, particularly in the US. It is a testament to the quality and commitment of our employees, all of whom are owners of the Company, that JTC continues to raise the bar. By 2020 JTC had doubled in size since listing in 2018 and by the end of this year, it will have doubled again. Based on our current strong performance and the very considerable potential for further significant organic growth in our business as well as in our M&A pipeline, we look forward to sharing highlights of our Cosmos era business plan for JTC's next stage of growth at our results in September. I would like to thank our excellent people for what JTC has achieved so far and their ambitions and commitment to continuing to deliver extraordinary growth in future".

 

 

Notice of Results

 

The Company will announce its interim results for the period ended 30 June 2022 on Tuesday 12 September 2023. An analyst briefing will be given by Nigel Le Quesne, Chief Executive Officer, and Martin Fotheringham, Chief Financial Officer, at 09:30 BST via audio conference.

 

Slides and an audio-cast of the presentation will be made available on the JTC website following the presentation. Those analysts wishing to dial into the audio conference are asked to contact Camarco jtc@camarco.co.uk.

.

 

Enquiries

JTC PLC

+44 (0) 1534 700 000

Nigel Le Quesne, Chief Executive Officer

Martin Fotheringham, Chief Financial Officer

David Vieira, Chief Communications Officer

Camarco

Geoffrey Pelham-Lane

+44 (0) 7733 124 226

Sam Morris

+44 (0) 7796 827 008

 

About JTC

JTC is a publicly listed, global professional services business with deep expertise in fund, corporate and private client services. Every JTC person is an owner of the business and this fundamental part of our culture aligns us with the best interests of all our stakeholders. Our purpose is to maximize potential and our success is built on service excellence, long-term relationships and technology capabilities that drive efficiency and add value.

www.jtcgroup.com

 

 


[1] https://www.jtcgroup.com/investor-relations/analyst-consensus/

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUSSORORUBUAR
Date   Source Headline
24th Apr 20247:00 amRNSPDMR Shareholding
22nd Apr 20243:51 pmRNSHolding(s) in Company
22nd Apr 20247:00 amRNSAcquisition of First Republic Trust Co of Delaware
18th Apr 20247:00 amRNSAnnual Financial Report and Notice of AGM
10th Apr 20247:00 amRNSVesting and Grant of Share Plan Awards
9th Apr 20247:00 amRNSFull year results for year ended 31 December 2023
20th Mar 20245:59 pmRNSHolding(s) in Company
4th Mar 20247:00 amRNSCompletion of Acquisition and Issue of Equity
29th Feb 202410:33 amRNSHolding(s) in Company
1st Feb 20247:00 amRNSPre-close Full Year Trading Update
31st Jan 20247:00 amRNSTotal Voting Rights
12th Jan 20247:00 amRNSPayment of SALI earnout and issue of equity
12th Dec 20234:39 pmRNSTR1: Notification of Major Holdings
7th Dec 20237:00 amRNSHolding(s) in Company
24th Nov 20237:00 amRNSAcquisition of Blackheath Capital Management LLP
22nd Nov 202310:22 amRNSHolding(s) in Company
3rd Nov 20237:05 amRNSHolding(s) in Company
2nd Nov 20237:00 amRNSHolding(s) in Company
25th Sep 20237:00 amRNSDirector's Share Dealing
19th Sep 20237:00 amRNSPDMR's Share Dealing
12th Sep 20237:00 amRNSInterim results for the period ended 30 June 2023
1st Sep 20239:00 amRNSTotal Voting Rights
10th Aug 202310:42 amRNSHolding(s) in Company
9th Aug 20231:57 pmRNSHolding(s) in Company
3rd Aug 20237:00 amRNSCompletion of SDTC Acquisition and Issue of Equity
25th Jul 20237:00 amRNSInterim Trading Update and Notice of Results
21st Jun 20237:00 amRNSIssue of Equity and Voting Rights
20th Jun 20239:43 amRNSHolding(s) in Company
15th Jun 20237:00 amRNSResults of Placing
14th Jun 20234:36 pmRNSProposed Placing of New Ordinary Shares
14th Jun 20234:35 pmRNSAcquisition of South Dakota Trust Company
9th Jun 20239:43 amRNSHolding(s) in Company
31st May 20237:00 amRNSTotal Voting Rights
24th May 20238:12 amRNSResult of AGM
4th May 20237:00 amRNSIssue of Equity and Voting Rights
21st Apr 20237:00 amRNSAnnual Financial Report and Notice of AGM
12th Apr 20237:00 amRNSVesting and Grant of Performance Share Plan Awards
11th Apr 20237:00 amRNSFull year results for year ended 31 December 2022
7th Mar 20231:57 pmRNSHolding(s) in Company
13th Feb 202312:08 pmRNSHolding(s) in Company
2nd Feb 20237:00 amRNSPre-close Full Year Trading Update
14th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20222:52 pmRNSFormation of Governance and Risk Committee
1st Nov 20227:00 amRNSCompletion of NYPTC Acquisition
13th Sep 20227:00 amRNSInterim results for the period ended 30 June 2022
26th Aug 20227:00 amRNSProposed Acquisition of NYPTC
27th Jul 20227:00 amRNSEIP Award Vesting
22nd Jul 20227:00 amRNSPre-close Interim Update and Notice of Results
15th Jul 20227:00 amRNSNomination Committee Appointment
8th Jul 202211:43 amRNSDirector's Share Dealing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.